In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 40 for your search:
Drug:  pegaspargase
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: UKALL2003, NCT00222612

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 14
Sponsor: Other
Protocol IDs: 2005-000658-56, 20040177, 2004-41-4276, NCT00192673

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011, NCT01501136

4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-2, NCT01501149

5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812

6.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 30
Sponsor: NCI
Protocol IDs: COG-AALL0433, AALL0433, NCT00381680

8.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-AALL0631, AALL0631, NCT00557193

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: NOPHO ALL2008 PEG Asparaginase, NCT00819351

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057

12.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617

13.

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to < 10
Sponsor: NCI
Protocol IDs: COG-AALL0932, AALL0932, NCT01190930

15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI
Protocol IDs: COG-AALL1131, AALL1131, NCT01406756

16.

Phase: Phase III
Type: Behavioral study, Treatment
Status: Active
Age: 1 to under 31
Sponsor: NCI, Other
Protocol IDs: CDR0000514500, COG-AALL0434, AALL0434, NCT00408005

17.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ALLR17, NCT00186875

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: 06-254, NCT00476190

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 16 to 39
Sponsor: NCI
Protocol IDs: CALGB-10403, CALGB 10403, ECOG C10403, SWOG C10403, NCT00558519

21.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 50
Sponsor: NCI
Protocol IDs: OSU-08066, OSU 08066, 2008C0112, DFCI-06254, NCT01005758

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-007, NCT00837200

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 31
Sponsor: NCI
Protocol IDs: COG-AALL07P1, AALL07P1, NCT00873093

24.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 60
Sponsor: Other
Protocol IDs: 2008LS112, 0810M50401, MT2008-29R, UMN-2008LS112, NCT00882206

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 40
Sponsor: Other
Protocol IDs: 2006-0375, NCT00866749
1   
New Search